Literature DB >> 11264189

Detection of viral interleukin-6 in Kaposi sarcoma-associated herpesvirus-linked disorders.

Y Aoki1, R Yarchoan, K Wyvill, S Okamoto , R F Little, G Tosato.   

Abstract

Expression of a viral interleukin-6 (vIL-6) has been detected in certain Kaposi sarcoma (KS)--associated herpesvirus positive (KSHV(+)) lesions. The release of vIL-6 systemically and its contribution to the pathogenesis of HIV-related malignancies was studied. Serum vIL-6 was detected in 13 (38.2%) of 34 HIV(+) patients with KS, in 6 (85.7%) of 7 HIV(+) patients with primary effusion lymphoma (PEL) and/or multicentric Castleman disease (MCD), and in 18 (60.0%) of 30 HIV(+), mostly homosexual, individuals without KS, MCD, or PEL. By contrast, serum vIL-6 was detected in only 3 (23.1%) of 13 patients with classic KS, 1 (2.5%) of 40 blood donors from the United States, and 4 (19.0%) of 21 blood donors from Italy. Circulating vIL-6 levels were associated with HIV(+) status (P <.0001). However, within the HIV(+) cohort, serum vIL-6 levels were not associated with the occurrence of KSHV-associated malignancies (P =.43). (Blood. 2001;97:2173-2176)

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11264189     DOI: 10.1182/blood.v97.7.2173

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  39 in total

1.  An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease.

Authors:  Thomas S Uldrick; Victoria Wang; Deirdre O'Mahony; Karen Aleman; Kathleen M Wyvill; Vickie Marshall; Seth M Steinberg; Stefania Pittaluga; Irina Maric; Denise Whitby; Giovanna Tosato; Richard F Little; Robert Yarchoan
Journal:  Clin Infect Dis       Date:  2010-08-01       Impact factor: 9.079

2.  Structural requirements for gp80 independence of human herpesvirus 8 interleukin-6 (vIL-6) and evidence for gp80 stabilization of gp130 signaling complexes induced by vIL-6.

Authors:  Daming Chen; John Nicholas
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

3.  Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease.

Authors:  Mark N Polizzotto; Thomas S Uldrick; Victoria Wang; Karen Aleman; Kathleen M Wyvill; Vickie Marshall; Stefania Pittaluga; Deirdre O'Mahony; Denise Whitby; Giovanna Tosato; Seth M Steinberg; Richard F Little; Robert Yarchoan
Journal:  Blood       Date:  2013-10-30       Impact factor: 22.113

4.  Sequence analysis of Kaposi sarcoma-associated herpesvirus (KSHV) microRNAs in patients with multicentric Castleman disease and KSHV-associated inflammatory cytokine syndrome.

Authors:  Alex Ray; Vickie Marshall; Thomas Uldrick; Robert Leighty; Nazzarena Labo; Kathy Wyvill; Karen Aleman; Mark N Polizzotto; Richard F Little; Robert Yarchoan; Denise Whitby
Journal:  J Infect Dis       Date:  2012-03-23       Impact factor: 5.226

5.  Kaposi's sarcoma-associated herpesviral IL-6 and human IL-6 open reading frames contain miRNA binding sites and are subject to cellular miRNA regulation.

Authors:  Jeong-Gu Kang; Vladimir Majerciak; Thomas S Uldrick; Xiaohong Wang; Michael Kruhlak; Robert Yarchoan; Zhi-Ming Zheng
Journal:  J Pathol       Date:  2011-08-24       Impact factor: 7.996

6.  Is tocilizumab safe in Kaposi sarcoma? A complex association among rheumatoid arthritis, psoriasis, and Kaposi sarcoma.

Authors:  Alice Verdelli; Diletta Bonciani; Veronica Bonciolini; Marzia Caproni
Journal:  Clin Drug Investig       Date:  2014-06       Impact factor: 2.859

7.  Modulation of Kaposi's sarcoma-associated herpesvirus interleukin-6 function by hypoxia-upregulated protein 1.

Authors:  Louise Giffin; Feng Yan; M Ben Major; Blossom Damania
Journal:  J Virol       Date:  2014-06-11       Impact factor: 5.103

8.  High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy.

Authors:  Thomas S Uldrick; Mark N Polizzotto; Karen Aleman; Deirdre O'Mahony; Kathleen M Wyvill; Victoria Wang; Vickie Marshall; Stefania Pittaluga; Seth M Steinberg; Giovanna Tosato; Denise Whitby; Richard F Little; Robert Yarchoan
Journal:  Blood       Date:  2011-04-12       Impact factor: 22.113

Review 9.  Kaposi sarcoma.

Authors:  Ethel Cesarman; Blossom Damania; Susan E Krown; Jeffrey Martin; Mark Bower; Denise Whitby
Journal:  Nat Rev Dis Primers       Date:  2019-01-31       Impact factor: 52.329

10.  Induction of Kaposi's Sarcoma-Associated Herpesvirus-Encoded Viral Interleukin-6 by X-Box Binding Protein 1.

Authors:  Duosha Hu; Victoria Wang; Min Yang; Shahed Abdullah; David A Davis; Thomas S Uldrick; Mark N Polizzotto; Ravindra P Veeranna; Stefania Pittaluga; Giovanna Tosato; Robert Yarchoan
Journal:  J Virol       Date:  2015-10-21       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.